Reducing the Harm of Medication - Recent Trends in Pharmacovigilance, Volume II

27K

views

78

authors

13

articles

Reducing the Harm of Medication - Recent Trends in Pharmacovigilance, Volume II

27K

views

78

authors

13

articles

Editorial

05 April 2023

Editorial: Reducing the harm of medication–recent trends in pharmacovigilance (volume II)

Elena Ramírez

,

Miguel González-Muñoz

,

Chanda Kulkarni

and

Francisco J. De Abajo

840 views

0 citations

Editors

4

Elena Ramírez

University Hospital La Paz

Francisco J De Abajo

University of Alcalá

Miguel Gonzalez-Muñoz

University Hospital La Paz

Chanda Kulkarni

iDD Research Solutions

Impact

About

This Research Topic is part of the Reducing the Harm of Medication – Recent Trends in Pharmacovigilance series (Volume I).

Four years ago, the World Health Organization (WHO) launched the third global health challenge, Medication Without Harm, which set out to achieve a reduction in iatrogenic medication related harm by 50% in 5 years. In this Research Topic, we aim to assess strategies to improve the safety of using medication to achieve this goal.

Medicines are a cornerstone of treatment for many health problems. There are many strategies for reducing adverse drug events (ADEs): labelling medications and solutions in hospitals, reconciling medication, improving prescription, and patient self-management skills education and training. However, research in the area is poorly organized among diseases, populations and environments. There are few strategies to help recognize that an ADE is caused by the drug, that is, if it is an adverse drug reaction (ADR). This can make it difficult for policymakers, health professionals, and others to find and use the evidence on how to address ADRs. In a pandemic situation where the most vulnerable patients are certain special populations (for example, the elderly) and patients with coexisting underlying diseases, the treatment of a new disease may conflict with existing treatment. Therefore, possibly now even more than before, the timely and accurate identification of ADRs is needed to improve results. The quality of data needs to be strengthened in order to:

• monitor medication-related harm, to improve medication safety through improved packaging and labelling
• evaluate the pharmacy benefit design to improve adherence to treatment and reduce self-medication
• evaluate the tools and technologies that empower patients to safety manage their own medications
• evaluate the impact of the strategies to reduce the harm of medication
• monitor the impact of COVID-19 treatments, including vaccines, on the population, with an emphasis on the most vulnerable, the elderly, children and pregnant women

The aim of this Research Topic is to assemble review articles and original research of ADE early detection, identification of the culprit drug and treatment strategies. ADE/ADR reporting programs around the world are collected. Strategies in preventing ADEs are very welcome. Preliminary opinions on the safety of the treatments currently used to treat patients with COVID-19 are also welcome.

Download ebook

PDF

EPUB

Share

Editors

Elena Ramírez

University Hospital La Paz

Francisco J De Abajo

University of Alcalá

Miguel Gonzalez-Muñoz

University Hospital La Paz

Chanda Kulkarni

iDD Research Solutions

Impact

26,989 Total views

20,240 Article views

5,806 Article downloads

943 Topic views

Published In

Frontiers in Pharmacology

Drugs Outcomes Research and Policies

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic